On October 1, 2024, the revised EBM (German Uniform Evaluation Standard) catalog for the fourth quarter of 2024 was published. The changes introduced mainly concerned updates of the contents (services legends, preambles of the several EBM subchapters). The newly introduced EBM codes relate to the co-funded study on cold plasma treatment for chronic wounds.

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients to better understand the potential scope of our support. From the week of October 21st, we are planning to work on 16 projects. Review the complete list of planned activities in this post.

Oleg Borisenko, Andrey Maslov and Agni Baka co-authored research titled "Utility of MpMRI and phi in detection of prostate cancer in Italy: a decision analytic modeling" presented on 3-5th of October 2024, in Bologna, Italy. The analysis aimed at the evaluation of clinical and cost consequences of different diagnostic options for prostate cancer in Italy. Read the abstract of the research here.

On October 9, 2024, the new version of the Nomenclature of Medical Biology Procedures (NABM 93) was released in France. Changes included the introduction of five new codes and wording modifications for several codes.

In September 2024, the Dutch Healthcare Institute (Zorginstituut Nederland, ZIN) announced two projects that received a subsidy under the "Subsidy scheme for promising care" in 2024 for research on the cost-effectiveness of cold plasma therapy for diabetic foot or venous leg wounds and intranasal mesenchymal stem cells in newborns with hypoxic-ischemic brain damage.

In October 2024, the updated version of the intra-DRG list was published in France. Three new devices were registered in the cardiovascular and neurovascular fields. Furthermore, one device was removed from the list, and the registration conditions for several devices were changed.

In October 2024, the Norwegian Directorate of Health released the Norwegian Clinical Procedure Coding (NKPK) system for 2025. A total of 15 new codes were introduced concerning cardiovascular, interventional radiology, neuromodulation, pulmonary, surgical procedures, and spine fields.

In September 2024, the National Institute for Health and Care Research (NIHR) in England released three MedTech-related assessments in its Health Technology Assessment (HTA) Journal, which concerned hyperthermic intraoperative peritoneal chemotherapy and cytoreductive surgery in peritoneal metastases, resuscitative endovascular balloon occlusion of the aorta in life-threatening torso hemorrhage, and clopidogrel resistance genotype testing. HTA Journal publishes research reports on the effectiveness, costs, and broader impact of health technologies for those who use, manage, and provide care in the NHS and informs National Institute for Health and Care Excellence (NICE) guidance.

On September 11, 2024, NHS England published an updated work plan for specialized clinical commissioning policies development. One MedTech-related policy was added to the program on long-term left ventricular assist devices (LVAD) for destination therapy in adults with heart failure. No new policies were published.

On September 16, 2024, the National Association of Statutory Health Insurance Physicians (KBV) and the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) announced that they had reached an agreement in financing negotiations concerning outpatient care.

In September 2024, the National Institute for Health and Care Excellence (NICE) published one new Interventional Procedures Guidance concerning single-step scaffold insertion for repairing symptomatic chondral knee defects.

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in September 2024. Five recommendations were published concerning the registration or modification of registration conditions/extension of indications for the medical devices in the List of Reimbursable Products and Services (LPPR). Opinions concern endocrine and spine devices, as well as medical aids.